Gregory A. Abel, MD, MPH

Gregory A. Abel, MD, MPH

Medical Oncology

Contact Information

Office Phone Number





617-632-6028 (new)


Gregory A. Abel, MD, MPH

Dr. Abel received his MD and MPH from Columbia University in 2000. He completed his postgraduate training in internal medicine at Massachusetts General Hospital and his hematology/oncology fellowship at Dana-Farber Cancer Institute. In 2007, he joined Dana-Farber and is a member of the Hematologic Malignancies staff, as well as the Center for Outcomes and Policy Research.



Director, Older Adult Hematologic Malignancy Program
Senior Physician
Associate Professor of Medicine, Harvard Medical School


Adult Leukemia Program
Older Adult Hematologic Malignancy (OHM) Program

Clinical Interests

Leukemia, Myelodysplastic syndromes, Myeloproliferative disorders

Diseases Treated

Board Certification

  • Internal Medicine, 2003
  • Oncology, 2007


  • Dana-Farber/Partners CancerCare, Hematology/Oncology


  • Massachusetts General Hospital, Internal Medicine

Medical School

  • Columbia University


    Health Services Research, Outcomes Research, Hematologic Malignancies

    Dr. Abel is an outcomes researcher and hematologic oncologist at Dana-Farber Cancer Institute (DFCI) and Harvard Medical School. He helps run DFCI’s Older Adult Hematologic Malignancy (OHM) geriatric hematology research program, serves as Co-Chair of the DFCI Ethics Advisory Committee, and directs DFCI’s Clinical Ethics Service. The Abel research lab applies health services research methods to understand the experiences of patients with blood cancers and develop interventions to improve their care. Dr. Abel is also interested in evaluating how cancer and its therapies affect outcomes such as function and quality of life. Through his work and collaboration with researchers in oncology, hematology, geriatrics, bioethics, and energy balance, he aims to ameliorate the impact of hematologic malignancies and their treatment from diagnosis to the end of life.


      • Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia. Haematologica. 2024 Apr 01; 109(4):1046-1052. View in: Pubmed

      • Natural history of clonal haematopoiesis seen in real-world haematology settings. Br J Haematol. 2024 Mar 24. View in: Pubmed

      • Race/ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia. J Natl Cancer Inst. 2024 Mar 22. View in: Pubmed

      • Validity and Reliability of a Smartphone Application for Home Measurement of Four-Meter Gait Speed in Older Adults. Bioengineering (Basel). 2024 Mar 06; 11(3). View in: Pubmed

      • Perspectives of Oncologists on the Ethical Implications of Using Artificial Intelligence for Cancer Care. JAMA Netw Open. 2024 Mar 04; 7(3):e244077. View in: Pubmed

      • Shifting from Equality toward Equity: Addressing Disparities in Research Participation for Clinical Cancer Research. J Clin Ethics. 2024; 35(1):8-22. View in: Pubmed

      • Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia. Blood Cancer J. 2023 12 21; 13(1):192. View in: Pubmed

      • Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis. Ann Intern Med. 2023 12; 176(12):1625-1637. View in: Pubmed

      • Digital Health to Patient-Facing Artificial Intelligence: Ethical Implications and Threats to Dignity for Patients With Cancer. JCO Oncol Pract. 2024 Mar; 20(3):314-317. View in: Pubmed

      • More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]. Blood Adv. 2023 10 24; 7(20):6275-6284. View in: Pubmed

      • Mortality among patients with diffuse large B-cell lymphoma and mental disorders: a population-based study. J Natl Cancer Inst. 2023 10 09; 115(10):1194-1203. View in: Pubmed

      • Perspectives on Transfusions for Hospice Patients With Blood Cancers: A Survey of Hospice Providers. J Pain Symptom Manage. 2024 Jan; 67(1):1-9. View in: Pubmed

      • Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study. Blood Adv. 2023 07 25; 7(14):3506-3515. View in: Pubmed

      • Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions. Blood Adv. 2023 07 25; 7(14):3749-3759. View in: Pubmed

      • Marital status, frailty, and survival in older adults with blood cancer. J Geriatr Oncol. 2023 Nov; 14(8):101589. View in: Pubmed

      • Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study. Lancet Haematol. 2023 Jul; 10(7):e530-e538. View in: Pubmed

      • Clinical ethics consultation documentation in the era of open notes. BMC Med Ethics. 2023 05 03; 24(1):27. View in: Pubmed

      • Benefits and Barriers of Technology for Home Function and Mobility Assessment: Perspectives of Older Patients With Blood Cancers, Caregivers, and Clinicians. JCO Clin Cancer Inform. 2023 04; 7:e2200171. View in: Pubmed

      • Yard Work. J Clin Oncol. 2023 Feb 08; JCO2202707. View in: Pubmed

      • Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trial. Cancer. 2023 04 01; 129(7):1075-1084. View in: Pubmed

      • Virtual frailty assessment for older adults with hematologic malignancies. Blood Adv. 2022 09 27; 6(18):5360-5363. View in: Pubmed

      • Ethics Consultation in Oncology: The Search for Quality in Quantity. JCO Oncol Pract. 2022 09; 18(9):610-613. View in: Pubmed

      • Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers. J Natl Compr Canc Netw. 2022 08; 20(8):915-923.e5. View in: Pubmed

      • A Process Framework for Ethically Deploying Artificial Intelligence in Oncology. J Clin Oncol. 2022 12 01; 40(34):3907-3911. View in: Pubmed

      • Peripheral blood CD3+ T-cell gene expression biomarkers correlate with clinical frailty in patients with haematological malignancies. Br J Haematol. 2022 10; 199(1):100-105. View in: Pubmed

      • Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. J Clin Oncol. 2022 11 10; 40(32):3709-3718. View in: Pubmed

      • Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies. Haematologica. 2022 05 01; 107(5):1172-1180. View in: Pubmed

      • Impact of Allocation on Survival During Intermittent Chemotherapy Shortages: A Modeling Analysis. J Natl Compr Canc Netw. 2022 04; 20(4):335-341.e17. View in: Pubmed

      • Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2022 02 24; 139(8):1246-1250. View in: Pubmed

      • Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States. Blood Adv. 2022 02 22; 6(4):1126-1136. View in: Pubmed

      • Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood Adv. 2021 11 09; 5(21):4352-4360. View in: Pubmed

      • Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. J Natl Cancer Inst. 2021 08 02; 113(8):1084-1093. View in: Pubmed

      • Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes. Transfusion. 2021 10; 61(10):2830-2836. View in: Pubmed

      • Prognostic value of disease risk score versus gait speed in older adults with lymphoma. Leuk Lymphoma. 2021 12; 62(12):2882-2889. View in: Pubmed

      • Advances in Management for Older Adults With Hematologic Malignancies. J Clin Oncol. 2021 07 01; 39(19):2102-2114. View in: Pubmed

      • Prevalence and Tolerance of Prognostic Uncertainty Among Thoracic Oncologists. Oncologist. 2021 08; 26(8):e1480-e1482. View in: Pubmed

      • Model solutions for ethical allocation during cancer medicine shortages. Lancet Haematol. 2021 04; 8(4):e246-e248. View in: Pubmed

      • Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Apr; 35(4):1223. View in: Pubmed

      • Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. PLoS One. 2021; 16(3):e0249087. View in: Pubmed

      • Objective performance tests of cognition and physical function as part of a virtual geriatric assessment. J Geriatr Oncol. 2021 11; 12(8):1256-1258. View in: Pubmed

      • US State Government Crisis Standards of Care Guidelines: Implications for Patients With Cancer. JAMA Oncol. 2021 02 01; 7(2):199-205. View in: Pubmed

      • Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment. Cancer. 2021 03 15; 127(6):875-883. View in: Pubmed

      • Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 04; 35(4):1166-1175. View in: Pubmed

      • American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020 08 11; 4(15):3528-3549. View in: Pubmed

      • Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. Leuk Lymphoma. 2020 12; 61(12):2900-2904. View in: Pubmed

      • Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review. J Clin Oncol. 2020 08 01; 38(22):2558-2569. View in: Pubmed

      • An Action Plan for Environmentally Sustainable Cancer Care. JAMA Oncol. 2020 04 01; 6(4):469-470. View in: Pubmed

      • Perspectives Regarding Hospice Services and Transfusion Access: Focus Groups With Blood Cancer Patients and Bereaved Caregivers. J Pain Symptom Manage. 2020 06; 59(6):1195-1203.e4. View in: Pubmed

      • Patient-hematologist discordance in perceived chance of cure in hematologic malignancies: A multicenter study. Cancer. 2020 03 15; 126(6):1306-1314. View in: Pubmed

      • Goals of care discussions for patients with blood cancers: Association of person, place, and time with end-of-life care utilization. Cancer. 2020 02 01; 126(3):515-522. View in: Pubmed

      • Patient-preferred outcomes measurement after post-mastectomy radiation therapy and immediate reconstruction. Breast J. 2020 02; 26(2):319-321. View in: Pubmed

      • Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019 11 01; 125(21):3845-3852. View in: Pubmed

      • Practical allocation system for the distribution of specialised care during cellular therapy access scarcity. J Med Ethics. 2019 08; 45(8):532-537. View in: Pubmed

      • Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood. 2019 07 25; 134(4):374-382. View in: Pubmed

      • The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. Leuk Lymphoma. 2019 12; 60(13):3161-3171. View in: Pubmed

      • Relationship between paid leave, financial burden, and patient-reported outcomes among employed patients who have undergone bone marrow transplantation. Qual Life Res. 2019 Jul; 28(7):1835-1847. View in: Pubmed

      • Function, Survival, and Care Utilization Among Older Adults With Hematologic Malignancies. J Am Geriatr Soc. 2019 05; 67(5):889-897. View in: Pubmed

      • Pentito. JAMA Oncol. 2019 04 01; 5(4):580. View in: Pubmed

      • Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019 10; 33(10):2393-2402. View in: Pubmed

      • Patients as experts: characterizing the most relevant patient-reported outcomes after hematopoietic cell transplantation. Bone Marrow Transplant. 2020 01; 55(1):242-244. View in: Pubmed

      • How Do Blood Cancer Doctors Discuss Prognosis? Findings from a National Survey of Hematologic Oncologists. J Palliat Med. 2019 06; 22(6):677-684. View in: Pubmed

      • The Best Medicine. JAMA Oncol. 2019 03 01; 5(3):350. View in: Pubmed

      • Cognitive Impairment Among Older Patients With Hematologic Cancers-Reply. JAMA Oncol. 2018 12 01; 4(12):1784. View in: Pubmed

      • What is the Role of the Arts in Medical Education and Patient Care? A Survey-based Qualitative Study. J Med Humanit. 2018 Dec; 39(4):431-445. View in: Pubmed

      • Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. J Geriatr Oncol. 2019 05; 10(3):486-489. View in: Pubmed

      • Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. Biol Blood Marrow Transplant. 2019 03; 25(3):599-605. View in: Pubmed

      • Perceptions of Oncologists About Sharing Clinic Notes with Patients. Oncologist. 2019 01; 24(1):e46-e48. View in: Pubmed

      • Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes. Am J Hematol. 2018 09; 93(9):1119-1126. View in: Pubmed

      • Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019 02; 24(2):247-254. View in: Pubmed

      • Meaningful changes in end-of-life care among patients with myeloma. Haematologica. 2018 08; 103(8):1380-1389. View in: Pubmed

      • Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncol. 2018 05 01; 4(5):686-693. View in: Pubmed

      • Cancer drug shortages: Awareness and perspectives from a representative sample of the US population. Cancer. 2018 05 15; 124(10):2205-2211. View in: Pubmed

      • Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival. Cancer Epidemiol Biomarkers Prev. 2018 03; 27(3):345-347. View in: Pubmed

      • What Does a Cancer Diagnosis Mean? Public Expectations in a Shifting Therapeutic Environment. J Oncol Pract. 2018 03; 14(3):139-140. View in: Pubmed

      • Management of older adults with myelodysplastic syndromes (MDS). J Geriatr Oncol. 2018 07; 9(4):302-307. View in: Pubmed

      • Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. Cancer. 2018 03 15; 124(6):1251-1259. View in: Pubmed

      • Frailty and the management of hematologic malignancies. Blood. 2018 02 01; 131(5):515-524. View in: Pubmed

      • Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017 Oct 24; 1(23):2032-2040. View in: Pubmed

      • Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PLoS One. 2017; 12(9):e0184747. View in: Pubmed

      • Aptitude; Mother's Day; Winter Beach. J Clin Oncol. 2017 Aug 20; 35(24):2848. View in: Pubmed

      • Why are patients with blood cancers more likely to die without hospice? Cancer. 2017 Sep 01; 123(17):3377-3384. View in: Pubmed

      • Self-reported sleep disturbance and survival in myelodysplastic syndromes. Br J Haematol. 2017 05; 177(4):562-566. View in: Pubmed

      • Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thromb Res. 2017 Feb; 150:53-58. View in: Pubmed

      • Assessing Quality of Care for the Myelodysplastic Syndromes. Curr Hematol Malig Rep. 2016 12; 11(6):402-407. View in: Pubmed

      • Direct-to-Consumer Drug Advertising in Oncology Is Not Beneficial to Patients or Public Health. JAMA Oncol. 2016 Nov 01; 2(11):1397-1398. View in: Pubmed

      • Small Step for Geriatric Oncology That Could Have Been a Giant Leap. J Clin Oncol. 2016 11 20; 34(33):4048-4049. View in: Pubmed

      • High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. J Natl Compr Canc Netw. 2016 10; 14(10):1274-1281. View in: Pubmed

      • Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016 Dec; 175(5):829-840. View in: Pubmed

      • Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. Leuk Lymphoma. 2017 04; 58(4):982-985. View in: Pubmed

      • Relationship between physician and patient assessment of performance status and survival in a large cohort of patients with haematologic malignancies. Br J Cancer. 2016 09 27; 115(7):858-61. View in: Pubmed

      • Barriers to Quality End-of-Life Care for Patients With Blood Cancers. J Clin Oncol. 2016 09 10; 34(26):3126-32. View in: Pubmed

      • Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016 Jun; 3(6):e276-83. View in: Pubmed

      • Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 08; 22(8):1504-1510. View in: Pubmed

      • Novel Data Sharing Between a Comprehensive Cancer Center and a Private Payer to Better Understand Care at the End of Life. J Pain Symptom Manage. 2016 08; 52(2):161-9. View in: Pubmed

      • Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica. 2016 06; 101(6):781-8. View in: Pubmed

      • Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes. Br J Haematol. 2016 06; 173(5):713-21. View in: Pubmed

      • Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer. 2016 Apr 15; 122(8):1209-15. View in: Pubmed

      • Timeliness of End-of-Life Discussions for Blood Cancers: A National Survey of Hematologic Oncologists. JAMA Intern Med. 2016 Feb; 176(2):263-5. View in: Pubmed

      • Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes. Am Soc Clin Oncol Educ Book. 2016; 35:e337-44. View in: Pubmed

      • Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML). J Clin Oncol. 2015 Oct 10; 33(29_suppl):206. View in: Pubmed

      • Impact of sleep disturbance in myelodysplastic syndromes (MDS). J Clin Oncol. 2015 Oct 10; 33(29_suppl):99. View in: Pubmed

      • Hospice Use Among Patients With Lymphoma: Impact of Disease Aggressiveness and Curability. J Natl Cancer Inst. 2016 Jan; 108(1). View in: Pubmed

      • Accessibility and Quality of Online Cancer-Related Clinical Trial Information for Naïve Searchers. Cancer Epidemiol Biomarkers Prev. 2015 Oct; 24(10):1629-31. View in: Pubmed

      • Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol. 2015 Jul; 6(4):288-98. View in: Pubmed

      • Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8. View in: Pubmed

      • Does surveillance imaging after treatment for diffuse large B-cell lymphoma really work? J Clin Oncol. 2015 May 01; 33(13):1427-9. View in: Pubmed

      • Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015 Apr 01; 121(7):1032-9. View in: Pubmed

      • Prevalence and impact of financial hardship among New England pediatric stem cell transplantation families. Biol Blood Marrow Transplant. 2015 Feb; 21(2):312-8. View in: Pubmed

      • Novel data sharing between a comprehensive cancer center and a private payer to better understand care at the end of life. J Clin Oncol. 2014 Oct 20; 32(30_suppl):1. View in: Pubmed

      • Quality of end-of-life care: Are blood cancers different? J Clin Oncol. 2014 Oct 20; 32(30_suppl):195. View in: Pubmed

      • Measuring quality of life in chronic hematologic malignancy: The QUALMS-1. J Clin Oncol. 2014 Oct 20; 32(30_suppl):263. View in: Pubmed

      • End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract. 2014 Nov; 10(6):e396-403. View in: Pubmed

      • Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS). Leuk Res. 2014 Dec; 38(12):1420-4. View in: Pubmed

      • Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma. 2015 Mar; 56(3):716-24. View in: Pubmed

      • Financial hardship and the intensity of medical care received near death. Psychooncology. 2015 May; 24(5):572-8. View in: Pubmed

      • Public advertising by cancer centers: are more data needed? Ann Intern Med. 2014 Jun 17; 160(12):870-1. View in: Pubmed

      • Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer. 2014 Jul 01; 120(13):1993-9. View in: Pubmed

      • Reply to quality control of bone marrow aspirates: additional steps toward a safer and more efficient procedure. Cancer. 2014 May 01; 120(9):1442. View in: Pubmed

      • Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood. 2014 Jan 16; 123(3):451-2. View in: Pubmed

      • Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014 Feb 01; 32(4):306-11. View in: Pubmed

      • A novel community-based delivery model to combat cancer disparities. Healthc (Amst). 2013 Dec; 1(3-4):123-9. View in: Pubmed

      • Using FastTrack to Implement an Academic Medical Center and Community Health Center Collaborative for Cancer Care Delivery. Healthc (Amst). 2013 Dec; 1(3-4):130-135. View in: Pubmed

      • An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 06; 123(6):837-42. View in: Pubmed

      • Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol. 2013 Nov; 163(4):487-95. View in: Pubmed

      • International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res. 2014 Apr; 23(3):825-36. View in: Pubmed

      • Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer. 2013 Oct 15; 119(20):3662-71. View in: Pubmed

      • Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist. Cancer. 2013 Oct 01; 119(19):3472-8. View in: Pubmed

      • Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res. 2013 Sep; 37(9):998-1003. View in: Pubmed

      • Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States. J Clin Oncol. 2013 Jun 01; 31(16):1984-9. View in: Pubmed

      • Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. Curr Opin Hematol. 2013 Mar; 20(2):150-6. View in: Pubmed

      • Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Leuk Lymphoma. 2013 Oct; 54(10):2155-62. View in: Pubmed

      • Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions. Cancer. 2013 Mar 01; 119(5):1065-72. View in: Pubmed

      • Comparative rates of adverse events with different formulations of intravenous iron. Am J Hematol. 2012 Nov; 87(11):E123-4. View in: Pubmed

      • Referrals for suspected hematologic malignancy: a survey of primary care physicians. Am J Hematol. 2012 Jun; 87(6):634-6. View in: Pubmed

      • Update on Direct-to-Consumer Marketing in Oncology. J Oncol Pract. 2012 Mar; 8(2):124-7. View in: Pubmed

      • High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma. 2012 Jun; 53(6):1113-6. View in: Pubmed

      • Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012 Mar 01; 119(9):2093-9. View in: Pubmed

      • Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012 Jun 01; 118(11):2944-51. View in: Pubmed

      • Sunlight exposure, vitamin D, and risk of non-Hodgkin lymphoma in the Nurses' Health Study. Cancer Causes Control. 2011 Dec; 22(12):1731-41. View in: Pubmed

      • The real world: CLL. Blood. 2011 Mar 31; 117(13):3481-2. View in: Pubmed

      • Cancer disparities in the context of Medicaid insurance: a comparison of survival for acute myeloid leukemia and Hodgkin's lymphoma by Medicaid enrollment. Oncologist. 2011; 16(8):1082-91. View in: Pubmed

      • Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia. Cancer. 2011 Apr 01; 117(7):1470-7. View in: Pubmed

      • Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program. Hematol Oncol. 2010 Sep; 28(3):133-6. View in: Pubmed

      • Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients. Leuk Res. 2010 Jul; 34(7):939-41. View in: Pubmed

      • Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment. J Clin Oncol. 2009 Sep 01; 27(25):4182-7. View in: Pubmed

      • Diagnostic delay and complications for older adults with multiple myeloma. Leuk Lymphoma. 2009 Mar; 50(3):392-400. View in: Pubmed

      • Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol. 2008 Nov 01; 26(31):5107-12. View in: Pubmed

      • Direct-to-consumer advertising for bleeding disorders: a content analysis and expert evaluation of advertising claims. J Thromb Haemost. 2008 Oct; 6(10):1680-4. View in: Pubmed

      • Delays in referral and diagnosis for chronic hematologic malignancies: a literature review. Leuk Lymphoma. 2008 Jul; 49(7):1352-9. View in: Pubmed

      • Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations. Am J Hematol. 2008 Jun; 83(6):519-20. View in: Pubmed

      • Chemotherapy as language: sound symbolism in cancer medication names. Soc Sci Med. 2008 Apr; 66(8):1863-9. View in: Pubmed

      • Direct-to-consumer advertising in oncology: a content analysis of print media. J Clin Oncol. 2007 Apr 01; 25(10):1267-71. View in: Pubmed

      • Direct-to-consumer advertising in oncology. Oncologist. 2006 Feb; 11(2):217-26. View in: Pubmed

      • Effects of biochemically confirmed smoking cessation on white blood cell count. Mayo Clin Proc. 2005 Aug; 80(8):1022-8. View in: Pubmed

      • Reporting enrollment in clinical trials. Ann Intern Med. 2002 Dec 17; 137(12):1007-8; author reply 1007-8. View in: Pubmed


      Location Avtar

      Brigham and Women's Hospital

      75 Francis Street Boston, MA 02115
      Get Directions

      Brigham and Women's Hospital

      Location Avtar

      Brigham and Women's Hospital

      75 Francis Street Boston, MA 02115
      Get Direction
      42.3362, -71.1067

      Ratings and Comments

      Gregory A. Abel, MD, MPH

      About Our Ratings

      Physician Star Rating Comment Block